Energen
http://www.energen.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Energen
Astex Bags Another Cancer Deal With MSD, This Time For ‘Undruggable’ p53 Target
The UK-based biotech will license its Pyramid platform to MSD to develop anticancer compounds targeting p53, a key transcription factor dubbed the ‘guardian of the genome’ that has proven highly complex and challenging to drug.
News We’re Watching: MedRhythms App Gets FDA Clearance, Recalls For Megadyne And Draeger, Elixir Stent Trial Moves Ahead
This week, companies including MedRhythms, Allergan and Urotronic announced FDA clearances; Quest and Envision launched a prostate cancer test; and the FDA designated two recalls as class I.
AstraZeneca Nabs CinCor’s Hypertension Asset In $1.3bn Acquisition
The UK major is acquiring CinCor in a deal that could be worth up to $1.8bn, in return getting hold of its Phase II hypertension candidate, baxdrostat, which offers combination potential with Farxiga.
AstraZeneca Takes Personalized Approach To Cell Therapy With Neogene Buy
The UK major has been building its cell therapy portfolio for about three years internally, oncology R&D chief Susan Galbraith tells Scrip, and the purchase of Neogene and its TCR-Ts targeting neoantigens in solid cancers is a logical step.
Company Information
- Other Names / Subsidiaries
-
- Energen Resource Corp., Alabama Gas Corp. (Alagasco)
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice